following a full submission:
lisdexamfetamine dimesylate (Elvanse®) is accepted for use within NHS Scotland.
Indication under review: as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
In a multi-centre, randomised, double-blind, controlled study in children and adolescents with ADHD, treatment with lisdexamfetamine was associated with a shorter time to first response compared with a non-stimulant, centrally-acting sympathomimetic agent. A greater proportion of lisdexamfetamine treated patients achieved improvements in symptom scores and functioning than those treated with the active comparator.
Download detailed advice164KB (PDF)
Medicine details
- Medicine name:
- lisdexamfetamine dimesylate (Elvanse)
- SMC ID:
- 863/13
- Indication:
- As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 May 2013